Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells

International Journal of Oncology

Volumn 42, Issue 6, 2013, Pages 1911-1918

  Hashimi, S M ^a   Yu, S ^a   Alqurashi, N ^a   Ipe, D S ^a   Wei, M Q ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Claudin 4; Head and neck cancer; Immunotoxin; Oncolytic Clostridiu

Indexed keywords

CLAUDIN 4; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN PSEUDOMONAS AERUGINOSA EXOTOXIN A; HYBRID PROTEIN; IMMUNOTOXIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CLOSTRIDIUM; CLOSTRIDIUM GHONII; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; CYTOTOXICITY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; PSEUDOMONAS AERUGINOSA;

ADP RIBOSE TRANSFERASES; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CLAUDIN-4; CLOSTRIDIUM; ENTEROTOXINS; EXOTOXINS; FEMALE; HEAD AND NECK NEOPLASMS; HELA CELLS; HUMANS; IMMUNOTOXINS; INHIBITORY CONCENTRATION 50; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS; VIRULENCE FACTORS;

EID: 84876543651     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1881     Document Type: Article

References (33)

1. Lucas R and Keisari Y: Innovative cancer treatments that augment radiotherapy or chemo-therapy by the use of immunotherapy or gene therapy. Recent Pat Anticancer Drug Discov 1: 201-208, 2006.
2. Krause G, Winkler L, Mueller SL, Haseloff R F, Piontek J and Blasig IE: Structure and function of claudins. Biochim Biophys Acta 1778: 631-645, 2008.
3. Lal-Nag M and Morin PJ: The claudins. Genome Biol 10: 235, 2009.
4. Saeki R, Kondoh M, Kakutani H, et al: A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol 76: 918-926, 2009.
5. Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606, 2005. (Pubitemid 41541431)
6. Suzuki M, Kato-Nakano M, Kawamoto S, et al: Therapeutic antitumor effcacy of monoclonal antibody against claudin-4 for pancreatic and ovarian cancers. Cancer Sci 100: 1623-1630, 2009.
7. Ling J, Liao H, Clark R, Wong MS and Lo DD: Structural constraints for the binding of short peptides to claudin-4 revealed by surface plasmon resonance. J Biol Chem 283: 30585-30595, 2008.
8. Michl P, Buchholz M, Rolke M, et al: Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 121: 678-684, 2001. (Pubitemid 32822583)
9. Pier GB, Boyer D, Preston M, et al: Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol 173: 5671-5678, 2004. (Pubitemid 39392155)
10. Phelan MC: Basic techniques in mammalian cell tissue culture. Curr Protoc Cell Biol Chapter 1: Unit 11, 2007.
11. Kurien BT and Scofeld RH: Introduction to protein blotting. Methods Mol Biol 536: 9-22, 2009.
12. Yao Q, Cao S, Li C, et al: Turn a diarrhoea toxin into a receptor-mediated therapy for a plethora of CLDN-4-overexpressing cancers. Biochem Biophys Res Commun 398: 413-419, 2010.
13. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983. (Pubitemid 14203433)
14. Dong H, Zhang Y, Dai Z and Li Y: Engineering Clostridium strain to accept unmethylated DNA. PLoS One 5: e9038, 2010.
15. Barbé S, Van Mellaert L and Anné J: The use of clostridial spores for cancer treatment. J Appl Microbiol 101: 571-578, 2006. (Pubitemid 44222287)
16. Litkouhi B, Kwong J, Lo CM, et al: Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfrin-gens enterotoxin. Neoplasia 9: 304-314, 2007. (Pubitemid 46608297)
17. Lanigan F, McKiernan E, Brennan DJ, et al: Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124: 2088-2097, 2009.
18. Ueda J, Semba S, Chiba H, et al: Heterogeneous expression of claudin-4 in human colorectal cancer: decreased claudin-4 expression at the invasive front correlates cancer invasion and metastasis. Pathobiology 74: 32-41, 2007. (Pubitemid 46745168)
19. Landers KA, Samaratunga H, Teng L, et al: Identifcation of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer. Br J Cancer 99: 491-501, 2008.
20. Kominsky SL, Vali M, Korz D, et al: Clostridium perfrin-gens enterotoxin elicits rapid and specifc cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 164: 1627-1633, 2004. (Pubitemid 38529765)
21. Barth S, Huhn M, Matthey B, et al: Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. Int J Cancer 86: 718-724, 2000. (Pubitemid 30249885)
22. Wei MQ, Mengesha A, Good D and Anné J: Bacterial targeted tumour therapy-dawn of a new era. Cancer Lett 259: 16-27, 2008. (Pubitemid 350245421)
23. Frederick BA, Helfrich BA, Coldren CD, et al: Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691, 2007. (Pubitemid 46954044)
24. Rangel LB, Agarwal R, D'Souza T, et al: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9: 2567-2575, 2003. (Pubitemid 36842098)
25. Li J, Sherman-Baust CA, Tsai-Turton M, Bristow RE, Roden RB and Morin PJ: Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer 9: 244, 2009.
26. Meertens L, Bertaux C, Cukierman L, et al: The tight junction proteins claudin-1,-6, and-9 are entry cofactors for hepatitis C virus. J Virol 82: 3555-3560, 2008. (Pubitemid 351429931)
27. Gourin CG and Podolsky RH: Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope 116: 1093-1106, 2006. (Pubitemid 44317932)
28. Al-Sarraf M: Treatment of locally advanced head and neck cancer: historical and critical review. Cancer Control 9: 387-399, 2002. (Pubitemid 35204461)
29. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006. (Pubitemid 43209104)
30. Wei MQ, Ipe D, Cao S and Hashimi S: Genetic Modifcation to Improve the Therapeutic Potential of Oncolytic Clostridia. In: Advances in Genetics Research. Urbano KV (ed). Vol 8. Nova Publishers, Hauppauge, NY, pp65-82, 2011.
31. Cao S, Cripps A and Wei MQ: New strategies for cancer gene therapy: progress and opportunities. Clin Exp Pharmacol Physiol 37: 108-114, 2010.
32. Theys J, Pennington O, Dubois L, et al: Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 95: 1212-1219, 2006. (Pubitemid 44658485)
33. Groot AJ, Mengesha A, van der Wall E, van Diest PJ, Theys J and Vooijs M: Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 364: 985-989, 2007. (Pubitemid 350087897)